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DSM-5: what is new and what is next?
The DSM-5 came out after all. It came with important 
changes, but with less innovation than some would 
expect. In the beginning of the review process, the DSM-
5 was announced as a paradigm change in psychiatry, 
by linking diagnosis to pathophysiology.1 However, the 
neurobiological findings available were not robust enough 
to allow inclusion in the classification system. Also, 
any proposed modification was carefully examined to 
protect psychiatric diagnosis, keeping a balance between 
sensitivity and specificity of diagnoses in psychiatry, and 
also to avoid deleterious consequences of any changes to 
criterion validity.2 However, classifications in psychiatry 
still lack predictive value and are not consistently 
associated with a causative explanation of phenomena 
in comparison with other areas of medicine.
Despite the caveats inherent to any classification 
system, the importance of the DSM-5 is undeniable, 
compiling information and facilitating clear 
communication in clinical and research fields. The 
major changes in DSM-5 classification were: a) focus 
on dimensional and developmental perspectives (in 
all disorders rather than only in a subgroup previously 
categorized as diagnoses first evidenced in childhood 
and adolescence); b) reordering of disorders and 
new grouping based on shared etiological factors; c) 
abandonment of the multi-axial structure; d) changes 
in existing diagnostic criteria for several disorders 
(after 5 years of evidence review); e) new diagnoses 
(i.e., hoarding disorders, disruptive mood dysregulation 
disorder (DMDD), binge eating disorder, premenstrual 
dysphoric disorder); and f) a chapter on disorders that 
need further study, e.g., attenuated psychosis syndrome 
and non-suicidal self-injury. 
Among the new diagnoses, DMDD is perhaps the 
most remarkable and controversial entity. Noteworthy, 
it is included in the depressive disorders chapter, 
calling attention to the fact that most children with 
DMDD develop major depressive disorder (not bipolar 
disorder) or generalized anxiety disorder when adults.3 
The rationale behind this new diagnostic category takes 
into account the debate that rates of bipolar disorder 
in children and adolescents have increased much faster 
than in adults.4 Some studies have attributed such high 
rates to changes in diagnostic practices, with children 
who lack traditional manic symptoms being diagnosed as 
bipolar on the basis of alternative symptoms – especially 
irritability.5 In this context, the diagnosis of severe 
mood dysregulation (SMD) emerged a decade ago6 as 
a differential diagnosis for bipolar disorder, given their 
different courses in adulthood. The DMDD diagnosis 
includes children and adolescences who present with 
hyperarousal along with irritability and frequent temper 
outbursts.7 
Of all changes made to existing diagnostic criteria, two 
are of particular impact: the elimination of mixed episodes 
from the bipolar disorders chapter and the modification of 
age of onset for attention-deficit/hyperactivity disorder 
(ADHD). Instead of mixed episodes, now ‘with mixed 
features’ is a possible specifier of any mood episode, 
recognizing the fact that there should always be a 
predominant polarity, with or without symptoms of the 
opposite pole (mixed features). This change brings 
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criteria closer to what was observed in clinical practice 
and improves the diagnosis of mixed features, with great 
implications for treatment approach. In ADHD, the DSM-5 
now requires that symptoms should be present before 12 
years of age (not anymore 7 years of age, as in the DSM-
IV). Several studies found no differences in phenotypic 
presentation, neuropsychological impairment, course, 
severity, or treatment response between children with 
onset of symptoms before or after 7 years of age.8 The 
medical and general community have voiced concerns 
that such a change may artificially increase the prevalence 
of ADHD, but evidence from population studies does not 
support this claim.9
A number of other changes were made to the DSM-5, 
and reviewing them is beyond the scope of this editorial. 
Complete reviews have been published elsewhere.1 In 
this issue of Trends in Psychiatry and Psychotherapy, 
an important article from DeSousa et al. provides 
methodological support to further studies on the new 
diagnosis proposed in the DSM-5, namely DMDD.10 
This is highly warranted, and will contribute to the 
understanding of the clinical value of this new diagnostic 
category in different cultures.
As per the DSM-5 preface, it was designed first and 
foremost to be a useful guide to clinical practice. And, 
as an official nomenclature, it must be applicable in a 
wide diversity of contexts.11 The DSM may also be a tool 
for collecting and communicating accurate mental health 
statistics. After all, in our view, it has achieved the goal 
of producing the best available evidence-based tool for 
the classification and description of mental disorders. 
There is always room for enhancement and updating. 
Even DSM-5 limitations have contributed to the 
acknowledgement that, in fact, the field of psychiatry has 
produced only modest progress over the last years. Clinical 
and basic research has grown, but is still a start-off area 
in psychiatry when compared to other areas of medicine. 
The expectations of greater input into the classifications 
coming from neurobiological research will depend on the 
success of future initiatives like the Research Domain 
Criteria (RDoC) project, proposed by the National Institute 
of Mental Health (NIMH). The rationale of RDOC and DSM-5 
are in opposite directions: the latter comes from the clinical 
observation of syndromes towards an understanding of 
their pathophysiology, and the former comes from the 
observation of basic neurobiological functions (or domains) 
towards an understanding of shared clinical features.12
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